In a long‐term follow‐up of patients with DLBCL treated with anti‐CD19 CAR‐T cells, 48% of treatments resulted in a DOR of over 3 years119 However, it is important to note that the characteristics of patients in L‐MIND differed from those in trials of CAR T‐cell therapy. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.